Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8325301 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL8327928 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6947539 | 0.93 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL9566453 | 0.88 | MEN1 (0.46) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL16984254 | 0.87 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18838292 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL2798935 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL18838469 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL18838470 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6361720 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0550025-A1 | Azaspiroheptanes and octanes and processes for their production | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-07-07 | — | — | EP | claimed |
| US-20210323981-A1 | FREE AMINO COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3883937-A1 | FREE AMINO COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-09-29 | — | — | EP | disclosed |
| EP-0641339-B1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5407943-A | Azaspiro quinolone antibacterial agents | PFIZER INC. (US) | 1995-04-18 | — | — | US | disclosed |
| EP-0641339-A1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0550025-A1 | Azaspiroheptanes and octanes and processes for their production | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-07-07 | — | — | EP | disclosed |
| WO-1992022550-A1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323981-A1 | FREE AMINO COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | ARG1, PNISR, ARGLU1 | SMN1; SMN2 3127/4885NPC1 2915/4885RAB9A 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.